Risk of Malignancy in Follicular Neoplasm on Thyroid Biopsy

Understanding Follicular Neoplasm Diagnosis

FNA cytology alone cannot definitively diagnose follicular thyroid carcinoma (FTC) as the diagnosis requires histological evidence of capsular and/or vascular invasion, which can only be determined after surgical excision, according to the National Comprehensive Cancer Network 3
The Bethesda Classification system, used by the American Joint Committee on Cancer, categorizes follicular neoplasm (Category IV) with an estimated malignancy risk of 15-40% 3
FNA cytology alone cannot definitively diagnose follicular thyroid carcinoma (FTC) as the diagnosis requires histological evidence of capsular and/or vascular invasion, which can only be determined after surgical excision, as stated by the European Society for Medical Oncology 1

Molecular diagnostics may help reclassify follicular lesions as more or less likely to be malignant based on genetic profile, as recommended by the National Comprehensive Cancer Network 3
If molecular testing suggests papillary thyroid carcinoma (especially BRAF V600E mutation), the risk of malignancy increases significantly, according to the American Thyroid Association 3

Due to the inability to determine malignancy without histological examination, most patients with follicular neoplasm on FNA undergo surgical excision (typically lobectomy) for definitive diagnosis, as suggested by the European Society for Medical Oncology 1
Molecular testing results, when available, should be interpreted in conjunction with clinical and ultrasound features to guide management decisions, as recommended by the National Comprehensive Cancer Network 3